Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and radiation in MSI-H/dMMR metastatic solid tumors
NCT04001101Phase 2Withdrawn
- Sponsor
- University of Colorado Denver
- Start
- Oct 2019
- Primary completion
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in metastatic solid tumors, colorectal cancer (CRC), sponsored by University of Colorado Denver. Planned start Oct 2019; status: withdrawn.
02
Drugs
03
Conditions
metastatic solid tumorscolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04001101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04001101.